---
schema_version: "secwatch.filing_event.v1"
accession: "0000886744-26-000003"
form_type: "8-K"
ticker: "GERN"
cik: "0000886744"
company_name: "GERON CORP"
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T11:00:12.042971+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Geron guides 2026 RYTELO revenue $220-240M; OPEX $230-240M

## Summary
- 2026 RYTELO net product revenue expected $220-240M.
- 2026 total operating expenses expected $230-240M.
- Amended Pharmakon term loan: Tranche B ($75M) and Tranche C ($50M) draw deadlines extended to July 30, 2026.
- Implemented strategic restructuring to streamline operations and support RYTELO commercial growth.
- Presented new IMerge trial analyses at ASH 2025 reinforcing RYTELO differentiation in LR-MDS.

## SEC filing metadata
- accession: 0000886744-26-000003
- form_type: 8-K
- ticker: GERN
- cik: 0000886744
- company_name: GERON CORP
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/886744/000088674426000003/0000886744-26-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/886744/000088674426000003/gern-20260112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000886744-26-000003
- JSON: https://secwatch.observer/filing/0000886744-26-000003.json
- Plain text: https://secwatch.observer/filing/0000886744-26-000003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.